RTA 402 Phase 3 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Diabetic Kidney Disease)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Aug 2019
Price : $35 *
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Acronyms AYAME
- Sponsors Kyowa Kirin
- 07 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Apr 2019 Planned number of patients changed from 700 to 950.
- 05 Jun 2018 New trial record